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Abstract
Background: Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the
safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab (arm
A), with trastuzumab plus vinorelbine (arm B) or with trastuzumab plus capecitabine (arm C), in patients with HER2-
positive metastatic breast cancer (MBC).
Methods: Eligible patients, with or without brain metastases, had received prior HER2-directed therapy. A dose-
escalation phase determined the tolerability of each combination and established a dose for further study. Further,
patients were recruited to expansion cohorts in each of the 3 arms to further explore efficacy and safety.
Results: The recommended doses of epertinib were 600 mg, 200 mg and 400 mg in arms A, B and C, respectively.
The most frequent grade 3/4 adverse event (AE) was diarrhoea in all arms, which was manageable with medical
intervention and dose modification. The objective response rate (complete response [CR] plus partial response [PR])
in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with
trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus
capecitabine was 56% (N = 9). Notably, 4 of 6 patients previously treated with T-DM1 responded in the arm A
expansion cohort (epertinib plus trastuzumab). In the arm C expansion cohort (epertinib plus trastuzumab plus
capecitabine), 4 of 7 patients responded despite previous exposure to capecitabine. Measurable regression of brain
metastases was observed in patients with CNS target lesions treated in both arms A and C.
Conclusion: We observed safety, tolerability and encouraging antitumour activity of epertinib combined with
trastuzumab, or with trastuzumab plus capecitabine. This supports further evaluation of these combinations in
patients with pre-treated HER2-positive MBC, with or without brain metastases.
Trial registration: EudraCT Number: 2013-003894-87; registered 09-September-2013.
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Background
Overexpression of the human epidermal growth factor
receptor 2 (HER2) is found in 15–20% of patients
with breast cancer and denotes an aggressive subtype
of the disease [1–3]. Outcomes have improved sub-
stantially with the development of trastuzumab and
subsequently other anti-HER2 agents including pertu-
zumab, ado-trastuzumab emtansine (T-DM1) and
lapatinib. Metastatic HER2-positive cancer will often
respond to sequential lines of HER2-targeted therapy,
indicating an ongoing dependence on HER2 signal-
ling. Hence, current management protocols comprise
first-line trastuzumab and pertuzumab with taxane
[4], and second-line T-DM1 [5]. Lapatinib and cape-
citabine are considered an option in the third-line
setting [6]. Given the development of resistance to
existing drugs, and the ongoing dependence on HER2,
there is a potential role for additional HER2-targeting
therapies. Furthermore, there remains an unmet need
for drugs with greater penetration of the central ner-
vous system (CNS).
Epertinib (S-222611, Shionogi & Co. Ltd., Osaka,
Japan) is an orally active, reversible, selective and po-
tent inhibitor of the epidermal growth factor receptor
(EGFR), HER2 and HER4 receptor tyrosine kinases.
Compared with lapatinib, epertinib showed more pro-
longed inhibition of phosphorylation of EGFR and
HER2 in vitro, and 4–6-fold greater antitumour po-
tency in mouse xenograft models [7]. Superior sur-
vival was also observed in a brain metastasis model of
breast cancer, with good penetration to CNS tumours
[7, 8]. A phase I study conducted in patients with
various solid tumours, driven by EGFR and/or HER2,
with or without brain metastases, demonstrated that
once-daily dosing of epertinib monotherapy at 800 mg
was well-tolerated [9, 10]. Promising antitumour ac-
tivity was also observed, particularly in HER2-positive
metastatic breast cancer (MBC), including partial re-
gression of brain metastases [9, 10].
In this study, we evaluated the safety, tolerability,
pharmacokinetics (PK) and efficacy of epertinib in com-
bination with trastuzumab, or with trastuzumab plus
chemotherapy (either vinorelbine or capecitabine). We
recruited heavily pre-treated patients with HER2-positive
breast cancer, with or without brain metastases, aiming
to determine the recommended dose of epertinib in each
combination and to select the most promising regimen
for future clinical studies.
Methods
Patients
Eligible patients were ≥ 18 years old with histologically
and/or cytologically confirmed HER2-positive metastatic
breast cancer who had previously been treated with any
anti-HER2 therapy and then progressed. To assess
expression of HER2, fresh tumour biopsies or archival
tissue were used, and HER2 status could be confirmed
by either central or local assessment. Other eligibility
criteria included measurable disease as per Response
Evaluation Criteria In Solid Tumours (RECIST) v1.1, an
Eastern Cooperative Oncology Group (ECOG) perform-
ance status of 0 or 1, and adequate bone marrow, renal,
hepatic and left ventricular function. Patients who had
previously received vinorelbine and/or capecitabine were
eligible, as were patients with brain metastases. Con-
comitant medication with strong CYP3A4 inhibitors/in-
ducers, or with CYP3A4 substrates with a narrow
therapeutic index, was prohibited. This study was
approved after review by the relevant regulatory and
independent ethics committees (EudraCT Number:
2013-003894-87) and was conducted in accordance with
the Declaration of Helsinki and International Conference
on Harmonization Good Clinical Practice. All patients
provided written informed consent before enrolment.
Study design and drug administration
This phase I/II, multi-centre, open-label study com-
prised dose-escalation and expansion components to
evaluate safety, tolerability, PK and preliminary antitu-
mour activity of epertinib administered orally once a day
in combination with trastuzumab (arm A), trastuzumab
plus vinorelbine (arm B) or trastuzumab plus capecita-
bine (arm C). Epertinib oral dosing started on day 3 of
cycle 1 (after 48 h PK blood sampling for capecitabine or
vinorelbine) and then administered continuously. The
protocol-specified duration of study treatment was 36
weeks unless there was radiographically documented dis-
ease progression or dose-limiting or intolerable toxicity.
After 36 weeks participants who were benefiting could
continue to receive epertinib via a separate named pa-
tient program.
In the dose-escalation component, a modified ‘3 + 3’
design was used to assess the safety and tolerability of
each combination. The dose of epertinib was escalated
from the initial dose (400 mg in arm A and 200 mg in
arms B and C) provided at least 3 subjects had com-
pleted 21 days’ treatment with no dose-limiting toxicity
(DLT). If any one of the first 3 subjects experienced
DLT, up to 4 further subjects were enrolled at that dose
level, with dose escalation proceeding if at least 6 sub-
jects completed 21 days’ treatment with no more than 1
DLT. Protocol-specified DLTs included uncomplicated
grade 4 neutropenia for ≥ 7 days or neutropenia of any
duration associated with fever > 38.5 °C, grade 3
thrombocytopenia associated with bleeding requiring
platelet transfusion; grade 3 or 4 non-haematologic tox-
icity (except incompletely treated nausea, vomiting, or
diarrhoea); persistent grade ≥ 2 diarrhoea or nausea and/
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or grade > 1 vomiting for 7 or more days despite sup-
portive care; and a decline in LVEF by ≥ 10% from
baseline.
Trastuzumab was given intravenously at 8 mg/kg as an
initial dose and subsequently 6 mg/kg, or at 600 mg/5
mL fixed dose subcutaneously, once every 3 weeks. Pa-
tients in arm B additionally received vinorelbine 60mg/
m2 orally on days 1 and 8 of a 21-day cycle, and patients
in arm C received capecitabine 1000 mg/m2 orally twice
daily for 14 days followed by a 7-day rest period (21-day
cycles). Loperamide could be used to treat diarrhoea but
was not used for prophylaxis. Arms were expanded up
to a further 9 evaluable patients to obtain confirmatory
tolerability and PK data to determine a recommended
dose for future clinical studies.
All adverse events (AEs) were monitored and coded
using National Cancer Institute (NCI) Common Termin-
ology Criteria for Adverse Events (CTCAE) Version 4.0.
Participants were treated until disease progression,
treatment-emergent toxicities or withdrawal of consent.
Pharmacokinetic analysis
Blood samples were assayed for PK profiles of the con-
comitant anticancer drugs (CADs) on 2 occasions, be-
fore (Day 1-3) and after (Day 22-24) introduction of
epertinib. Dosing with epertinib commenced orally once
per day on day 3, after the last blood sample of the first
CDA PK profile. PK profiles of the CAD in presence of
epertinib and epertinib (its active de-alkylated and lac-
tam metabolites) were obtained when the patient had re-
ceived at least 10 consecutive days of combination
therapy. PK sampling was performed at the following
times during treatment; pre dose, 1, 2, 4, 6, 8, 12, 24 and
48 hours post dose for analysis of vinorelbine, and pre
dose, 0.5, 1, 2, 4, 6, 8, and 12 hours post dose for cape-
citabine and its major metabolites (5-fluorouracil and
alpha-fluoro-beta-alanin). The blood samples on day 22
and 23 were analysed for PK analysis of epertinib, and
its active de-alkylated and lactam metabolites (pre dose,
1, 2, 4, 6, 8, 12 and 24 hours post dose).
Tumour evaluation
Tumour response was assessed by each investigator at
6- to 9-week intervals according to RECIST v1.1. Pa-
tients who had at least one additional scan after the
baseline or patients who had no additional scan but dis-
continued due to clinical disease progression were con-
sidered evaluable for response. The objective response
rate (ORR), comprising the proportion of patients
achieving complete response (CR) or partial response
(PR), and clinical benefit rate (CBR; the proportion of
patients achieving CR, PR or stable disease [SD] ≥ 6
months) were summarised.
Results
A total of 45 patients with HER2-positive metastatic
breast cancer were enrolled between August 2014 and
November 2015 at 8 sites in the UK and France. Patient
demographics and baseline characteristics are sum-
marised in Table 1. Of the 45 patients enrolled, 38 (84%)
had received at least 4 lines of prior anti-cancer therapy.
All 45 patients (100%) had previously received trastuzu-
mab, 31 (69%) had also received T-DM1 and 19 (42%)
had received lapatinib. Patient disposition is summarised
in Additional file 1: Figure S1.
Safety and tolerability
Adverse events occurring in at least 10% of patients are
summarised in Table 2. Overall, the most frequently re-
ported AEs were diarrhoea, nausea, increased bilirubin,
decreased appetite and vomiting. Diarrhoea was gener-
ally managed with drugs such as loperamide and some-
times by holding and/or reducing the dose of epertinib.
Grade 3 diarrhoea was reported in 16 patients (36%)
with a median duration of 3 days and maximum
Table 1 Patient demographics and baseline characteristics
Arm A
(N=21)
Arm B
(N=7)
Arm C
(N=17)
Overall
(N=45)
Epertinib + T Epertinib + T + V Epertinib + T + C
Sex
Female 21 (100%) 6 (85.7%) 17 (100%) 44 (97.8%)
Male 0 1 (14.3%) 0 1 (2.2%)
Age (years)
Mean
(range)
57.6 (38-79) 49.0 (36-57) 56.8 (36-75) 56.0 (36-79)
ECOG PS at screening
0 11 (52.4%) 6 (85.7%) 11 (64.7%) 28 (62.2%)
1 10 (47.6%) 1 (14.3%) 6 (35.3%) 17 (37.8%)
Number of metastatic sites at screening
1-3 7 (33.3%) 4 (57.1%) 5 (29.4%) 16 (35.6%)
≥4 14 (66.7%) 3 (42.9%) 12 (70.6%) 29 (64.4%)
Number of prior anti-cancer therapy regimens
1-3 0 1 (14.3%) 6 (35.3%) 7 (15.6%)
≥4 21 (100%) 6 (85.7%) 11 (64.7%) 38 (84.4%)
Prior HER2-targeted therapy
Trastuzumab 21 (100%) 7 (100%) 17 (100%) 45 (100%)
T-DM1 15 (71.4%) 3 (42.9%) 13 (76.5%) 31 (68.9%)
Lapatinib 10 (47.6%) 2 (28.6%) 7 (41.2%) 19 (42.2%)
Pertuzumab 3 (14.3%) 2 (28.6%) 4 (23.5%) 9 (20.0%)
Prior Capecitabine / Vinorelbine
Capecitabine 16 (76.2%) 4 (57.1%) 11 (64.7%) 31 (68.9%)
Vinorelbine 9 (42.9%) 1 (14.3%) 10 (58.8%) 20 (44.4%)
Abbreviations: T trastuzumab, V vinorelbine, C capecitabine, ECOG Eastern
cooperative oncology group, PS performance status
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Table 2 Treatment-emergent adverse events occurring in ≥ 10% of patients
Grade Arm A (N=21) Arm B (N=7) Arm C (N=17) Overall (N=45)
Epertinib + T Epertinib + T + V Epertinib + T + C
all, n (%) ≥3, n (%) all, n (%) ≥3, n (%) all, n (%) ≥3, n (%) all, n (%) ≥3, n (%)
Gastrointestinal disorders
Diarrhoea 20 (95.2) 8 (38.1) 7 (100) 3(42.9) 16 (94.1) 5 (29.4) 43 (95.6) 16 (35.6)
Nausea 17 (81.0) 1 (4.8) 7 (100) 0 12 (70.6) 0 36 (80.0) 1 (2.2)
Vomiting 7 (33.3) 1 (4.8) 4 (57.1) 1 (14.3) 6 (35.3) 0 17 (37.8) 2 (4.4)
Stomatitis 6 (28.6) 0 0 0 5 (29.4) 0 11 (24.4) 0
Constipation 3 (14.3) 0 2 (28.6) 0 3 (17.6) 0 8 (17.8) 0
Abdominal Pain 4 (19.0) 0 1 (14.3) 0 2 (11.8) 0 7 (15.6) 0
Dyspepsia 1 (4.8) 0 1 (14.3) 0 3 (17.6) 0 5 (11.1) 0
Metabolism and nutrition disorders
Decreased appetite 9 (42.9) 0 2 (28.6) 0 6 (35.3) 1 (5.9) 17 (37.8) 1 (2.2)
Hypokalaemia 4 (19.0) 0 1 (14.3) 1 (14.3) 6 (35.3) 3 (17.6) 11 (24.4) 4 (8.9)
General disorders
Fatigue 5 (23.8) 0 3 (42.9) 1 (14.3) 6 (35.3) 0 14 (31.1) 1 (2.2)
Oedema peripheral 2 (9.5) 0 0 0 4 (23.5) 0 6 (13.3) 0
Pyrexia 2 (9.5) 0 2 (28.6) 0 2 (11.8) 0 6 (13.3) 0
Asthenia 1 (4.8) 0 0 0 4 (23.5) 0 5 (11.1) 0
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome 2 (9.5) 0 0 0 11 (64.7) 1 (5.9) 13 (28.9) 1 (2.2)
Rash 5 (23.8) 0 2 (28.6) 0 4 (23.5) 0 11 (24.4) 0
Pruritus 6 (28.6) 0 0 0 2 (11.8) 0 8 (17.8) 0
Dermatitis acneiform 6 (28.6) 0 0 0 0 0 6 (13.3) 0
Blood system disorders
Anaemia 3 (14.3) 1 (4.8) 0 0 6(35.3) 0 9 (20.0) 1 (2.2)
Neutropenia 1 (4.8) 0 4 (57.1) 4 (57.1) 2(11.8) 1 (5.9) 7 (15.6) 5 (11.1)
Infections and infestations
Paronychia 1 (4.8) 0 2 (28.6) 0 6 (35.3) 0 9 (20.0) 0
Upper respiratory tract infection 3 (14.3) 0 2 (28.6) 0 1 (5.9) 0 6 (13.3) 0
Urinary tract infection 2 (9.5) 0 0 0 4 (23.5) 0 6 (13.3) 0
Respiratory disorders
Dyspnoea 2 (9.5) 1 (4.8) 1 (14.3) 0 5 (29.4) 1 (5.9) 8 (17.8) 2 (4.4)
Epistaxis 3 (14.3) 0 2 (28.6) 0 3 (17.6) 0 8 (17.8) 0
Cough 3 (14.3) 0 1 (14.3) 0 2 (11.8) 0 6 (13.3) 0
Nervous system disorders
Headache 4 (19.0) 0 1 (14.3) 0 2(11.8) 0 7 (15.6) 0
Lethargy 2 (9.5) 0 3 (42.9) 0 1 (5.9) 0 6 (13.3) 0
Musculoskeletal disorder
Muscle spasms 2 (9.5) 0 1 (14.3) 0 2 (11.8) 0 5 (11.1) 0
Eye disorder
Dry eye 1 (4.8) 0 1 (14.3) 0 3 (17.6) 0 5 (11.1) 0
Investigations
Blood bilirubin increased 10 (47.6) 1 (4.8) 2 (28.6) 0 10 (58.8) 3 (17.6) 22 (48.9) 4 (8.9)
ALT increased 3 (14.3) 0 5 (71.4) 0 2 (11.8) 1 (5.9) 10 (22.2) 1 (2.2)
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duration of 8 days per event. Nausea and vomiting were
generally low grade. Blood bilirubin elevation, previously
reported with epertinib [9, 10], was not associated with
elevation of liver enzymes or haematological abnormal-
ities, except for one patient who experienced liver dys-
function which was subsequently shown to be due to
progression of hepatic metastases. Neutropenia was ob-
served in arm B (57%). The incidence of palmar-plantar
erythrodysaesthesia was greatest in arm C (65%).
In arm A, grade 3 diarrhoea during the first 21-day
period of daily dosing with epertinib was observed in 4
of 7 patients at the 800-mg dose level. Although only 1
formal DLT was observed, this dose was not considered
to be well-tolerated, and therefore, 600 mg was the dose
recommended for further study of this combination with
trastuzumab. Four of 9 patients in the 600 mg cohort
had a dose reduction because of AEs, but no patients
permanently discontinued treatment because of toxicity.
In arm B, 200mg was determined as the maximum tol-
erable dose (MTD) because 2 patients in the 400-mg co-
hort experienced DLTs (grade 4 neutropenia > 7 days,
N = 2). No patient in the 200-mg cohort discontinued
treatment because of AEs. In arm C, 600 mg was not
considered to be well-tolerated because withdrawal of
the study drug due to grade 3 diarrhoea lasting less than
7 days (N = 1), or blood bilirubin elevation (N = 1), was
required in 2 of the 4 patients during cycle 1. Although
these were not pre-defined DLTs, 400 mg was defined as
the recommended dose. Two of 9 patients in the 400-
mg cohort required dose reduction of epertinib because
of AEs, but no permanent discontinuation was required.
No grade 5 toxicity was observed across all arms.
Pharmacokinetic analysis
No relevant differences between treatment arms, or in
the presence and absence of concomitant drugs, were
found in PK parameters for epertinib and its metabolites
(Additional file 3: Table S1). Similarly, the presence of
epertinib appeared to have no significant effect on the
PK of vinorelbine and capecitabine (Additional file 3:
Tables S2-S4). PK analysis was not performed in the
400-mg cohort in arm B due to temporary drug discon-
tinuation for safety purposes during cycle 1.
Antitumour activity
Forty-four of the 45 patients enrolled were evaluable for
tumour response. One patient discontinued without any
efficacy evaluation due to DLT at 800 mg in arm A. The
tumour response for each arm and dose are summarised
in Table 3. The magnitude of response and duration of
treatment for patients receiving epertinib at the clinically
recommended dose or MTD in arms A, B and C are
summarised in Fig. 1 a and b.
In arm A, the ORR at 600mg epertinib was 67% (6/9
patients). Notably, 4 of 6 patients pre-treated with T-
DM1, and 5 of 7 patients pre-treated with capecitabine,
Table 3 Antitumour activity in evaluable patients
Dose of epertinib Arm A Arm B Arm C
Epertinib + T Epertinib + T + V Epertinib + T + C
400mg 600mg 800mg 200mg 400mg 200mg 400mg 600mg Overall
N=5 N=9 N=7 N=5 N=2 N=4 N=9 N=4 N=45
BOR
CR 0 0 0 0 0 0 0 0 0
PR 0 6 (66.7%) 1 (14.3%) 0 2 (100%) 0 5 (55.6%) 2 (50.0%) 16 (35.6%)
SD ≥ 6 months 2 (40.0%) 0 1 (14.3%) 4 (80.0%) 0 1 (25.0%) 0 1 (25.0%) 9 (20.0%)
CBR 2 (40.0%) 6 (66.7%) 2 (28.6%) 4 (80.0%) 2 (100%) 1 (25.0%) 5 (55.6%) 3 (75.0%) 25 (55.6%)
PD 2 (40.0%) 1 (11.1%) 2 (28.6%) 0 0 1 (25.0%) 1 (11.1%) 1 (25.0%) 8 (17.8%)
Clinical benefit is defined as objective response plus SD at 6 months
Abbreviations: T trastuzumab, V vinorelbine, C capecitabine, BOR best overall response, CR complete response, PR partial response, SD stable disease, CBR clinical
benefit rate, PD progressive disease
Table 2 Treatment-emergent adverse events occurring in ≥ 10% of patients (Continued)
Grade Arm A (N=21) Arm B (N=7) Arm C (N=17) Overall (N=45)
Epertinib + T Epertinib + T + V Epertinib + T + C
all, n (%) ≥3, n (%) all, n (%) ≥3, n (%) all, n (%) ≥3, n (%) all, n (%) ≥3, n (%)
AST increased 2 (9.5) 0 3 (42.9) 0 4 (23.5) 1 (5.9) 9 (20.0) 1 (2.2)
Weight decreased 2 (9.5) 0 0 0 3 (17.6) 0 5 (11.1) 0
Abbreviations: T trastuzumab, V vinorelbine, C capecitabine
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experienced PR in this cohort. Two of 3 patients with
brain metastases achieved PR as assessed by RECIST v1.1
in this cohort. In arm B, since there was no tumour re-
sponse in the first 5 patients treated with 200mg and,
given concerns that there may be insufficient exposure to
epertinib at this dose, no additional patients were enrolled.
However, the clinical benefit rate was 80%. In arm C, the
ORR at 400mg was 56% (5/9 patients). Interestingly, 4 of
Fig. 1 Antitumour activity (a) and duration on treatment (b) for patients in the recommended dose cohorts for each arm. Partial regression of
brain metastases in a 53-year-old patient after 59 days of treatment with epertinib 400 mg in combination with trastuzumab plus capecitabine in
arm C (c). Brain metastases first appeared during prior treatment with trastuzumab with capecitabine, and the patient underwent whole-brain
radiotherapy followed by T-DM1. After further progression in the brain the patient was enrolled in this study. T: trastuzumab, L: lapatinib, K: T-
DM1, P: pertuzumab, V: vinorelbine, C: capecitabine, BM: brain metastases
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7 patients previously treated with capecitabine experi-
enced PR in this cohort. One of two patients with brain
metastases showed partial regression of CNS lesions as
assessed by RECIST v1.1 (Fig. 1c). Across cohorts, a re-
duction in the longest diameter was observed in 4 of 5 pa-
tients with CNS target lesions (Additional file 2: Figure
S2). This included all patients treated in the recom-
mended dose cohorts (arm A; N = 2 and arm C; N = 2).
Discussion
In combination with trastuzumab, 600mg daily of epertinib
was defined as the recommended dose based on the safety
data. The most frequently occurring AE in this cohort was
diarrhoea, which could be managed by anti-diarrhoeal medi-
cation and/or dose reduction. At this dose, epertinib plus
trastuzumab showed a remarkable response rate (67%) in pa-
tients heavily treated with regimens including trastuzumab,
T-DM1, lapatinib, pertuzumab and chemotherapy. This may
indicate greater efficacy for dual therapy with trastuzumab,
given the 19% response rate that was observed with epertinib
monotherapy at a higher dose of 800mg in HER2-positive
MBC [10]. Additional benefit for combination with trastuzu-
mab over single agent epertinib, despite previous disease
progression on a trastuzumab-containing regimen, would be
consistent with observations with other HER2-directed
tyrosine kinase inhibitors. For example, the combination of
lapatinib plus trastuzumab was superior to lapatinib
monotherapy in HER2-positive MBC that had progressed on
trastuzumab in terms of median progression-free survival
(PFS), although not response rate [11].
In clinical practice, trastuzumab is often continued be-
yond progression with a switch to an alternative combin-
ation chemotherapy agent, as this improves outcomes
compared with chemotherapy alone [12]. Standard first-
line therapy in MBC is trastuzumab plus taxane with or
without pertuzumab, and the chemotherapy regimens
tested with epertinib and trastuzumab in this trial where
chosen with this standard of care in mind. In combination
with trastuzumab plus vinorelbine, 200mg of epertinib
was defined as MTD because of grade 4 neutropenia [13].
There was no pharmacological interaction between eperti-
nib 200mg and vinorelbine based on plasma exposure, al-
though a PK analysis could not be completed in the two
patients treated in the 400mg cohort because of drug ces-
sation related to the DLTs. Since neutropenia has not
been reported in patients receiving monotherapy with
epertinib [9, 10], or observed in arms A or C our study, it
is likely that it was attributable to the vinorelbine in arm
B. At an epertinib dose of 200mg in combination with
trastuzumab plus vinorelbine, there were no tumour re-
sponses in the first 5 patients and so recruitment to this
arm was halted.
Trastuzumab plus capecitabine combination therapy is
considered to be effective in heavily pre-treated HER2-
positive MBC [12, 14]. The PHEREXA study has demon-
strated that the addition of pertuzumab to trastuzumab
plus capecitabine did not significantly improve PFS [15];
objective response rates were 33% with trastuzumab plus
capecitabine, and 41% with pertuzumab and trastuzu-
mab plus capecitabine. Although we cannot draw direct
comparisons, in our study the objective response rate
with epertinib 400 mg in combination with trastuzumab
plus capecitabine was 56%, despite prior capecitabine
treatment in 7 of 9 patients, supporting further investi-
gation of this regimen.
Capecitabine plus lapatinib has been approved in
HER2-positive MBC previously treated with trastuzumab
and is often favoured for patients with brain metastases
[16]. Combining chemotherapy with HER2-directed
therapy for the management CNS disease is further sup-
ported by the activity of capecitabine plus neratinib in
patients with treatment-refractory brain metastases
treated within the TBCRC 022 study [17]. The CNS re-
sponse rate of 49% compared favourably to the 8% re-
sponse rate that was previously reported for a TBCRC
022 neratinib monotherapy cohort [18]. In our study,
prolonged disease stabilisation (≥ 6 months) was seen in
2 of 3 patients with brain metastases in arm A, and a
partial response in brain metastases occurred in one of 2
patients in arm C. All patients had received prior radio-
therapy and experienced subsequent CNS progression.
We have recently reported that both epertinib and lapa-
tinib accumulate to a comparable extent in tumour de-
posits of a rapidly growing mouse brain metastasis
model. By contrast, only epertinib accumulates in brain
metastases derived from a slow-growing tumour cell
line, in which the blood-tumour barrier can be consid-
ered to be intact [8]. These pre-clinical observations,
combined with our clinical findings, suggest that eperti-
nib may be particularly effective in preventing or con-
trolling brain metastases in patients.
Conclusions
Combination therapy of epertinib with trastuzumab
showed robust antitumour activity with manageable
diarrhoea even in heavily pre-treated patients. Epertinib
in addition to trastuzumab, with or without capecitabine,
could be an effective regimen to treat refractory HER2-
positive breast cancer, including those patients with
CNS metastases, and merits further clinical evaluation.
Additional files
Additional file 1: Figure S1. Patient disposition. (TIFF 7122 kb)
Additional file 2: Figure S2. Waterfall plot of maximum relative brain
tumour reduction (as per RECISTv1.1) in comparison to baseline in all
patients with CNS target lesions (N = 5). One column represents one
patient. (TIFF 7122 kb)
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Additional file 3: Table S1. Summary of Geometric Mean (Geometric
CV%) Pharmacokinetics Parameters for Epertinib and its Metabolites with
concomitant anticancer drugs (CADs). Table S2. Summary of Geometric Mean
(Geometric CV%) Pharmacokinetics Parameters for Vinorelbine with and
without Epertinib (Arm B). Table S3. Summary of Geometric Mean (Geometric
CV%) Pharmacokinetics Parameters for Capecitabine with and without
Epertinib (Arm C). Table S4. Summary of Geometric Mean (Geometric CV%)
Pharmacokinetics Parameters for 5-Fluorouracil following treatment with Cape-
citabine with and without Epertinib (Arm C) (DOCX 52 kb)
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